Ceritinib-associated hyperglycemia in the Japanese Adverse Drug Event Report Database

Haruka Fujita1, Takaaki Murakami1, Fumiaki Tomoike2, Daisuke Yabe1, Nobuya Inagaki1

1Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, 2Department of Life science, Faculty of Science, Gakushuin University, Tokyo, and 3Department of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Seki, Japan

INTRODUCTION

Genetic alterations in anaplastic lymphoma kinase (ALK), a member of the insulin receptor protein-tyrosine kinase superfamily, are implicated in the pathogenesis of several human cancers1,2. In non-small-cell lung cancer (NSCLC), ALK rearrangement occurs in approximately 3–7% of patients3. NSCLC harboring ALK rearrangements is sensitive to ALK inhibitors (ALKIs), including crizotinib and alectinib; invariable ALK resistance to these drugs remains a clinical issue. Recently, ceritinib, a second-generation ALKI, has been proven effective for patients having disease progression during crizotinib and/or alectinib treatment3,4. However, systemic metabolisms affected by ceritinib have not been fully investigated.

Recently, a case of possible ceritinib-induced hyperglycemia was reported5. The association between ceritinib and hyperglycemia remains controversial. In the previous clinical trials of ceritinib, the occurrence of hyperglycemia was not noted in a phase 3 trial. In contrast, a limited number of hyperglycemia cases were reported in phase 1 and 2 trials; however, the adverse events were summarized regardless of the exact relationship between cause and effect6–8. Furthermore, it is recognized that crizotinib and alectinib have no effect on patients’ glucose tolerance5, whereas the prescribing information of crizotinib and alectinib showed that hyperglycemia occurred in 1.1% of patients who received crizotinib and in <5% of patients who received alectinib, respectively. The exact relationship between each ALK inhibitor and hyperglycemia remains a clinical issue to be resolved, which can benefit the better choice for lung cancer and diabetes treatment.

We therefore carried out disproportional analysis using the Japanese Adverse Drug Event Report (JADER) database, which contains all pharmacovigilance data based on spontaneous reports of adverse events between April 2004 and November 2018 to the Pharmaceuticals and Medical Devices Agency. The reporting odds ratio of ceritinib for hyperglycemia was 2.25 (95% confidence interval [CI] 1.24–4.08), whereas those of crizotinib and alectinib were 0.07 (95% CI 0.01–0.40) and 0.94 (95% CI 0.30–2.94), respectively. Among reported events without antidiabetes agent use, the reporting odds ratio of ceritinib was still 2.54 (95% CI 1.27–5.12). Thus, the possibility of hyperglycemia should be carefully monitored in patients receiving ceritinib.

METHODS

As of March 2019, the database contained 887,636 reports of adverse drug reactions. We extracted cases of “suspected medicine” for adverse effects. For the present study, ethics approval was unnecessary, as the JADER database is open access and the data were downloaded from the website (http://www.pmda.go.jp) according to the Pharmaceuticals and Medical Devices Agency’s instructions12,13. The potential signals of ALKIs (ceritinib, crizotinib, alectinib) with hyperglycemia and other

Keywords
Anaplastic lymphoma kinase, Ceritinib, Drug-induced hyperglycemia

Correspondence
Nobuya Inagaki
Tel: +81-75-751-3560
Fax: +81-75-751-4244
E-mail address: inagaki@kuhp.kyoto-u.ac.jp

J Diabetes Investig 2020; 11: 726–730
doi: 10.1111/jdi.13168
hyperglycemia-related events were assessed with categories using the ROR. The signals of acetaminophen and corticosteroids (prednisolone and dexamethasone), the associations of which with hyperglycemia are well established, were also analyzed. The ROR was calculated using a two-by-two contingency table. The ROR was considered significant when the lower bound of the two-sided 95% confidence interval (CI) for the risk of hyperglycemia was >1.0, as previously reported. The 51 terms indicating hyperglycemia or diabetes in the Standardized MedDRA Queries 20000041 or antidiabetes agents were selected, as previously described. The data were analyzed using JMP Pro (version 14.3; SAS Institute, Tokyo, Japan).

RESULTS

Analysis of RORs in the entire data of JADER

In the database, 7,837 cases of hyperglycemia-related events were found in 887,636 reports of adverse drug reactions. Only ceritinib showed significant ROR of the three ALKIs (Table 1). In the ceritinib-associated reports, 429 patients started ceritinib use before September 2017, and four of them showed hyperglycemia. In contrast, 132 patients started ceritinib use after September 2017, and seven of them had hyperglycemia. The RORs of initial ceritinib use before and after September 2017 were 1.06 (95% CI 0.39–2.83) and 6.29 (95% CI 2.94–13.5), respectively.

Analysis of RORs in the antidiabetes agent-excluded data of JADER

We additionally analyzed the data in which antidiabetes agents were excluded as suspected medicine according to previous reports. Subsequently, 4,744 cases of hyperglycemia-related events were found in 814,273 reports of adverse drug reactions. Of ALKIs, the ROR was found to be significant only in ceritinib; in both crizotinib and alectinib, the RORs were insignificant (Table 2).

Characteristics of cases reported as ceritinib-associated hyperglycemia in JADER

A total of 11 cases of hyperglycemia suspected to be associated with ceritinib were reported in the JADER database. Their detailed clinical characteristics are described in Table 3. All of the cases harbored NSCLC. Eight of them had diabetes mellitus as a comorbidity, and three of them underwent insulin treatment. No cases were reported under treatment of corticosteroids.

DISCUSSION

Targeting of tyrosine kinases is a major cancer therapeutic strategy today. At the same time, unexpected endocrine and metabolic adverse effects of such therapies have been observed, and heightened vigilance is required. Because of the remarkable sensitivities of NSCLCs to selective ALKIs, ALKIs have become promising therapies. Ceritinib was approved in 2014 for ALK-positive metastatic NSCLC for patients who had progressed or were intolerant to crizotinib by the US Food and Drug Administration and in 2016 by the Ministry of Health, Labor and Welfare of Japan. Expanded use as first-line treatment for patients with metastatic NSCLC was approved in 2017 by both the US Food and Drug Administration and Ministry of Health, Labor and Welfare of Japan. As common adverse events of ceritinib, gastrointestinal reactions, such as diarrhea and nausea, as well as liver enzyme elevations have been reported, whereas its involvement in hyperglycemia remains to be clarified.

In the present study, we comprehensively overviewed the occurrence of hyperglycemia associated with ALKIs using the JADER database. As a result, ceritinib was found to show a significant ROR in both entire and antidiabetes agent-excluded analyses, which showed an association with hyperglycemia in clinical settings. The discrete time period analysis based on the expanding application of ceritinib in Japan showed that the ROR in the cases with initial ceritinib use before September 2017 was insignificant, although the RORs after September 2017 and during the entire period were significant. The insignificant ROR before September 2017 might be biased because of the limited case application and/or possible prior use of crizotinib or alectinib. In contrast, crizotinib and alectinib showed insignificant RORs, consistent with the results of their clinical trials.

ROR is a useful statistical method for the evaluation of association between a specific drug and rare adverse events. Although the number of reported cases treated with ceritinib...
was limited, the present results show reasonable statistical associations between ceritinib and hyperglycemia. In the previous study of drug-induced hyperglycemia using JADER, ceritinib was not mentioned, but the present findings on corticosteroids and acetaminophen are consistent. Considering that we used the same candidate terms and antidiabetes agents for the analysis, this discrepancy might be due to the fact that we used the newer dataset of JADER and that ceritinib was relatively recently released on the market.

The underlying mechanism of ceritinib-associated hyperglycemia remains unclear. Generally, selectivity of tyrosine kinase inhibitors depends on the structure of the adenosine triphosphate-binding sites, Asp-Phe-Gly motif-1 and gatekeepers (Figure 1a,b). As shown Figure 1a, the amino acid residues in the adenosine triphosphate-binding sites and Asp-Phe-Gly motif-1 of ALK are similar to that of the insulin receptor (INSR). Actually, according to the prescribing information, ceritinib blocked INSR with greater potency than crizotinib and alectinib (IC50: 7 vs 290 vs 550 nmol/L). Thus, the potency of the INSR block might account for ceritinib-associated hyperglycemia. In this context, the efficacy of ceritinib on the ALK L1196M mutant that is resistant to crizotinib and alectinib can provide an additional key to clarify the differing influence on glucose tolerance among the ALKIs (Figure 1c). Ceritinib accessibility to the ALK L1196M gatekeeper mutation might lead to possible inhibition of INSR, the gatekeeper of which is the same amino acid residue, methionine.

Finally, spontaneous reporting systems, including the JADER database, have limitations in terms of inherent biases and lack of data on controls. Therefore, we note that ROR does not reflect the exact prevalence rate. The contribution of coexisting illnesses, drug dose, the exposure period or the prior use of anticancer drug were not investigated; additional clinical monitoring and analytical observational studies are required. In the present study, most affected patients had prior diabetes mellitus, and some received insulin therapy. The descriptions of antidiabetes agents were not found for some diabetes patients (Table 3). However, it is difficult to judge whether they did not use any antidiabetes drugs or if the information was lacking. Although ceritinib might be likely to affect diabetes patients lacking compensatory insulin secretion capacity, further studies to clarify this susceptibility are warranted.

In conclusion, ROR analysis using the JADER database shows that ceritinib might be significantly associated with hyperglycemia in clinical settings. Clinicians including diabetologists and oncologists should emphasize vigilance for ceritinib-associated hyperglycemia.

### Table 2 | Number of reports and reporting odds ratio of hyperglycemia without antidiabetes agents use

| Drug                | No. cases | No. non-cases | Total no. reports | ROR   | 95% CI       |
|---------------------|-----------|---------------|-------------------|-------|--------------|
| Ceritinib           | 8         | 537           | 545               | 2.54  | 1.27–5.12    |
| Crizotinib          | 1         | 1,858         | 1,859             | 0.092 | 0.013–0.65   |
| Alectinib           | 3         | 318           | 321               | 1.61  | 0.52–5.02    |
| Crizotinib and alectinib | 4     | 2,176         | 2,180             | 0.31  | 0.12–0.84    |
| Prednisolone       | 670       | 25,534        | 26,204            | 5.05  | 4.65–5.48    |
| Dexamethasone      | 87        | 9,364         | 9,451             | 1.60  | 1.29–1.98    |
| Acetaminophen      | 9         | 4,581         | 4,590             | 0.33  | 0.17–0.64    |

95% CI, 95% confidence interval; ROR, reporting odds ratio.

### Table 3 | Clinical characteristics of cases with ceritinib-associated hyperglycemia

| Case | Sex | Age | Comorbidity | Concomitant drugs |
|------|-----|-----|-------------|-------------------|
| 1    | M   | 70s | DM          | Loperamide hydrochloride, Metoclopramide, bifidobacterium |
| 2    | F   | 60s | DM, HT, dyslipidemia, subclavian vein thrombosis | Amlodipine besylate, edoxaban tosilate hydrate, metoclopramide |
| 3    | M   | 80s | N/R         | N/R               |
| 4    | M   | NA  | DM, valvular disease | N/R            |
| 5    | M   | NA  | DM, HT      | N/R               |
| 6    | F   | 80s | N/R         | N/R               |
| 7    | F   | 70s | DM          | Insulin           |
| 8    | F   | 70s | DM, HT, CKD | Insulin aspart, degludec |
| 9    | F   | 70s | DM, HT, CKD | Insulin aspart, degludec |
| 10   | F   | NA  | N/R         | NR                |
| 11   | M   | 70s | DM          | NR                |

CKD, chronic kidney disease; DM, diabetes mellitus; F, female; HT, hypertension; M, male; NA, not available; NR, not reported.
Figure 1 | The structure comparison on ceritinib affinity between anaplastic lymphoma kinase (ALK) and insulin receptor (INSR). (a) The amino acid residues in the adenosine triphosphate (ATP)-binding and Asp-Phe-Gly (DFG) motif sites of wild-type ALK (ALK[WT]), ALK(L1196M) and INSR. Gatekeeper, red; DFG motif-1, blue. (b) Ribbon diagram of the structure of the ALK (WT) catalytic domain obtained from the Protein Data Bank (ID: 4mkc) was visualized with UCSF Chimera version 1.13.1, University of California, San Francisco, CA, USA. The model of the ceritinib-binding domain is shown in the black square.24 ALK (WT), orange; ceritinib, sky blue; gatekeeper, gray circle; DFG motif and ATP-binding site of ALK, purple. (c) The structural similarities between INSR and ALK (L1196M) might be related to their susceptibilities to ceritinib. Gatekeeper M is shown in the gray circle. The ribbon diagram structures of the INSR kinase domain (Protein Data Bank ID: 1ir3) and ALK (L1196M) catalytic domain (ID: 4cd0) were visualized with UCSF Chimera version 1.13.1. The model of the ceritinib-binding domains is shown in the black square. INSR, light green; ALK (L1196M), orange; gatekeeper, gray circle; DFG motif and ATP-binding site of ALK, purple.
ACKNOWLEDGMENT
We appreciate the JADER database contributors.

DISCLOSURE
DY received research grants from Nippon Boehringer Ingelheim, Eli Lilly, Taisho-Toyama. MSD, Takeda, Ono and Novo Nordisk. NI received research funds from Mitsubishi Tanabe, Daiichi Sankyo and AstraZeneca; speaker honoraria from Kowa; scholarship grants from Kissei, Taisho-Toyama, Sanofi, Takeda, Japan Tobacco, Kyowa Kirin, Sumitomo Dainippon, Astellas, MSD, Eli Lilly, Ono, Sanwa Kagaku, Pfizer, Nippon Boehringer Ingelheim, Novo Nordisk, Novartis and Teijin.

REFERENCES
1. Yamaoka T, Kusumoto S, Ando K, et al. Receptor tyrosine kinase-targeted cancer therapy. Int J Mol Sci 2018; 19: E3491.
2. Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol 2016; 27: iii4–iii15.
3. Shaw AT, Kim DW, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol 2016; 27: iii4–iii15.
4. Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 2014; 20: 5686–5696.
5. Sakuma I, Nagano H, Yoshino I, et al. Ceritinib aggravates glycemic control in insulin-treated patients with diabetes and metastatic ALK-positive lung cancer. Intern Med 2019; 58: 817–820.
6. Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase positive non-small cell lung cancer. Clin Cancer Res 2015; 21: 2436–2439.
7. Crino L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol 2016; 34: 2866–2873.
8. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomized, open-label, phase 3 study. Lancet 2017; 389: 917–929.
9. Nakao S, Hatahira H, Sasaoka S, et al. Evaluation of drug-induced photosensitivity using the Japanese Adverse Drug Event Report (JADER) Database. Biol Pharm Bull 2017; 40: 2158–2165.
10. Van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3–10.
11. Sakaeda T, Tarnon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 2013; 10: 796–803.
12. Arii M, Shirakawa J, Konishi H, et al. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug report database. Diabetes Care 2018; 41: e130–e132.
13. Konishi H, Shirakawa J, Arii M, et al. Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes. Endocr J 2019; 66: 571–574.
14. Robert R Jr. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacol Res 2017; 117: 343–356.
15. Illouz F, Braun D, Briet C, et al. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol 2014; 171: R91–R99.
16. Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review. Leuk Res 2014; 38: 1392–1398.
17. Hida T, Seto T, Horinouchi H, et al. Phase II study of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9. Cancer Sci 2018; 109: 2863–2872.
18. Malik SM, Maher VE, Bijwaard KE, et al. Food and Drug Administration approval: crizotinib for treatment of Advanced or Metastatic Non-Small cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive. Clin Cancer Res 2014; 20: 2029–2034.
19. Ou SH, Ahn JS, De Petris L, et al. Alectinib in Crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global Study. J Clin Oncol 2016; 34: 661–668.
20. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus ceritinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017; 377: 829–838.
21. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study); a single-arm, open-label, phase 1–2 study. Lancet Oncol 2013; 14: 590–598.
22. Murakami T, Yabe D, Inagaki N. Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology. J Diabetes Investig 2019; 10: 1168–1170.
23. Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007; 50: 409–424.
24. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014; 4: 662–673.